Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!

ReviR Therapeutics develops medicines that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases. The company combines genomics, functional genomics, and an…

ReviR Therapeutics develops medicines that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases. The company combines genomics, functional genomics, and an…
Founded: 2021
Focus: RNA-targeting therapeutics for cancer, rare genetic disorders, and infectious diseases
Platform: AI/ML-driven RNA discovery and design (VoyageR) plus splice-modulation capabilities (SpliceR)
Recent funding: Series A $30,000,000 (2024-07-26); latest Grant round dated 2025-01-30
Founders / leadership: Peng Yue (Co‑founder & CEO) and Yang Li
Developing therapeutics that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases.
2021
Biotechnology
30,000,000 USD
Series A announced/closed Jul 26, 2024; participating investors include Lapam Capital, 5Y Capital, CDH Investments, XtalPi, Yael Capital Management Limited, and CMT Research Foundation (as listed in funding details).
Latest funding round listed as a Grant dated Jan 30, 2025; amount not specified in the provided evidence; recent investors associated with the company include the California Institute for Regenerative Medicine (CIRM) and Lapam Capital.
“Syndicate includes venture investors (e.g., Lapam Capital, 5Y Capital, CDH Investments, XtalPi, Yael Capital) and a regional/public funder (California Institute for Regenerative Medicine); Series A led by Lapam Capital.”
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
60,000+
Open Roles
400+
New This Week